Technical Analysis for CERC - Cerecor Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.61 | -4.04% | -0.11 |
Earnings due: May 5
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical CERC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | -4.04% | |
| Down 3 Days in a Row | Weakness | -4.04% | |
| Lower Bollinger Band Touch | Weakness | -4.04% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 3x Volume Pace | about 15 hours ago |
| 2x Volume Pace | about 15 hours ago |
| 1.5x Volume Pace | about 15 hours ago |
| Down 5% | about 15 hours ago |
| Down 3% | about 15 hours ago |
Get a Trading Assistant
- Earnings date: 05/05/2021
Cerecor Inc. Description
Cerecor, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs for the treatment of patients with neurological and psychiatric disorders. The company has a portfolio of clinical and preclinical compounds, such as CERC-301, CERC-501, and CERC-406. It develops CERC-301 that is in Phase II development stage as an oral, adjunctive antidepressant for the treatment of patients with major depressive disorder (MDD); CERC-501, which is in Phase II development, for co-occurring psychiatric and substance use disorders; and CERC-406 that is its preclinical lead candidate that inhibit catechol-O-methyltransferase within the brain, as well as anticipates developing CERC-406 for the treatment of residual cognitive impairment symptoms in patients with MDD. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor, Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Disorders Symptoms Organic Chemistry Major Depressive Disorder Depressive Disorder Depression Echo Piperidines Antidepressants Psychiatric Disorders Pyrrolidines Cognitive Impairment Nmda Receptor Antagonists Substance Use Disorder
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.49 |
| 52 Week Low | 1.97 |
| Average Volume | 671,119 |
| 200-Day Moving Average | 2.76 |
| 50-Day Moving Average | 3.36 |
| 20-Day Moving Average | 3.02 |
| 10-Day Moving Average | 2.91 |
| Average True Range | 0.23 |
| ADX | 14.4 |
| +DI | 22.55 |
| -DI | 26.95 |
| Chandelier Exit (Long, 3 ATRs ) | 2.85 |
| Chandelier Exit (Short, 3 ATRs ) | 3.13 |
| Upper Bollinger Band | 3.41 |
| Lower Bollinger Band | 2.63 |
| Percent B (%b) | -0.03 |
| BandWidth | 25.87 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.12 |
| MACD Histogram | -0.0265 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.02 | ||||
| Resistance 3 (R3) | 3.01 | 2.86 | 2.95 | ||
| Resistance 2 (R2) | 2.86 | 2.76 | 2.87 | 2.92 | |
| Resistance 1 (R1) | 2.74 | 2.70 | 2.67 | 2.75 | 2.90 |
| Pivot Point | 2.59 | 2.59 | 2.56 | 2.60 | 2.59 |
| Support 1 (S1) | 2.47 | 2.49 | 2.40 | 2.48 | 2.32 |
| Support 2 (S2) | 2.32 | 2.43 | 2.33 | 2.30 | |
| Support 3 (S3) | 2.20 | 2.32 | 2.27 | ||
| Support 4 (S4) | 2.21 |
